Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

British Journal of Haematology

Volumn 169, Issue 3, 2015, Pages 423-434

  Mishima, Yuko ^a   Santo, Loredana ^a   Eda, Homare ^a   Cirstea, Diana ^a   Nemani, Neeharika ^a   Yee, Andrew J ^a   O'Donnell, Elizabeth ^a   Selig, Martin Karl ^b   Quayle, Steven N ^c   Arastu Kapur, Shirin ^d   Kirk, Christopher ^d   Boise, Lawrence H ^e   Jones, Simon S ^c   Raje, Noopur ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Acetylon Pharmaceuticals Inc   (United States)

^d ONYX PHARMACEUTICALS   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggresome; Carfilzomib; HDAC6 inhibitor; Multiple myeloma; Proteasome inhibitor

Indexed keywords

CARFILZOMIB; HISTONE DEACETYLASE 6; RICOLINOSTAT; UBIQUITIN; VIMENTIN; 2-(DIPHENYLAMINO)-N-(7-(HYDROXYAMINO)-7-OXOHEPTYL)PYRIMIDINE-5-CARBOXAMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; OLIGOPEPTIDE; PROTEASOME INHIBITOR; PYRIMIDINE DERIVATIVE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ELECTRON MICROSCOPY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; LYSOSOME; MOLECULAR DYNAMICS; MONONUCLEAR CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; ANIMAL; AUTOPHAGY; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENETICS; METABOLISM; PATHOLOGY; PHAGOSOME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; FEMALE; HETEROGRAFTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHAGOSOMES; PROTEASOME INHIBITORS; PYRIMIDINES;

EID: 84927691932     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13315     Document Type: Article

References (47)

1. Catley, L., Weisberg, E., Tai, Y.T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J. & Anderson, K.C. (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615-2622.
2. Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Munshi, N., Kharbanda, S. & Anderson, K.C. (2003) JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. Journal of Biological Chemistry, 278, 17593-17596.
3. Costes, S.V., Daelemans, D., Cho, E.H., Dobbin, Z., Pavlakis, G. & Lockett, S. (2004) Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophysical Journal, 86, 3993-4003.
4. Dimopoulos, M., Siegel, D.S., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., Hungria, V., Spencer, A., Palumbo, A., Graef, T., Eid, J.E., Houp, J., Sun, L., Vuocolo, S. & Anderson, K.C. (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology, 14, 1129-1140.
5. Fribley, A.M., Evenchik, B., Zeng, Q., Park, B.K., Guan, J.Y., Zhang, H., Hale, T.J., Soengas, M.S., Kaufman, R.J. & Wang, C.Y. (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. Journal of Biological Chemistry, 281, 31440-31447.
6. Herndon, T.M., Deisseroth, A., Kaminskas, E., Kane, R.C., Koti, K.M., Rothmann, M.D., Habtemariam, B., Bullock, J., Bray, J.D., Hawes, J., Palmby, T.R., Jee, J., Adams, W., Mahayni, H., Brown, J., Dorantes, A., Sridhara, R., Farrell, A.T. & Pazdur, R. (2013) U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clinical Cancer Research, 19, 4559-4563.
7. Hideshima, T. & Anderson, K.C. (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer, 2, 927-937.
8. Hideshima, T., Hayashi, T., Chauhan, D., Akiyama, M., Richardson, P. & Anderson, K. (2003a) Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene, 22, 8797-8801.
9. Hideshima, T., Richardson, P. & Anderson, K.C. (2003b) Novel therapeutic approaches for multiple myeloma. Immunological Reviews, 194, 164-176.
10. Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. & Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 8567-8572.
11. Hideshima, T., Mazitschek, R., Santo, L., Mimura, N., Gorgun, G., Richardson, P.G., Raje, N. & Anderson, K.C. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia, 28, 457-460.
12. Hoang, B., Benavides, A., Shi, Y., Frost, P. & Lichtenstein, A. (2009) Effect of autophagy on multiple myeloma cell viability. Molecular Cancer Therapeutics, 8, 1974-1984.
13. Kabeya, Y., Mizushima, N., Yamamoto, A., Oshitani-Okamoto, S., Ohsumi, Y. & Yoshimori, T. (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. Journal of Cell Science, 117, 2805-2812.
14. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A. & Yao, T.P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115, 727-738.
15. Kawaguchi, T., Miyazawa, K., Moriya, S., Ohtomo, T., Che, X.F., Naito, M., Itoh, M. & Tomoda, A. (2011) Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. International Journal of Oncology, 38, 643-654.
16. Knaevelsrud, H. & Simonsen, A. (2010) Fighting disease by selective autophagy of aggregate-prone proteins. FEBS Letters, 584, 2635-2645.
17. Kopito, R.R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology, 10, 524-530.
18. Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. & Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281-3290.
19. Kuhn, D.J., Berkova, Z., Jones, R.J., Woessner, R., Bjorklund, C.C., Ma, W., Davis, R.E., Lin, P., Wang, H., Madden, T.L., Wei, C., Baladandayuthapani, V., Wang, M., Thomas, S.K., Shah, J.J., Weber, D.M. & Orlowski, R.Z. (2012) Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood, 120, 3260-3270.
20. Lee, J.Y., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y.S., Pandey, U.B., Kaushik, S., Tresse, E., Lu, J., Taylor, J.P., Cuervo, A.M. & Yao, T.P. (2010) HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO Journal, 29, 969-980.
21. Liu, X.D., Ko, S., Xu, Y., Fattah, E.A., Xiang, Q., Jagannath, C., Ishii, T., Komatsu, M. & Eissa, N.T. (2012) Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. Journal of Biological Chemistry, 287, 19687-19698.
22. Marx, J. (2006) Autophagy: is it cancer's friend or foe? Science, 312, 1160-1161.
23. McConkey, D. (2010) Proteasome and HDAC: who's zooming who? Blood, 116, 308-309.
24. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jäck, H.M. & Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783-1792.
25. Michallet, A.S., Mondiere, P., Taillardet, M., Leverrier, Y., Genestier, L. & Defrance, T. (2011) Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS ONE, 6, e25820.
26. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. & Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540-545.
27. Mizushima, N., Levine, B., Cuervo, A.M. & Klionsky, D.J. (2008) Autophagy fights disease through cellular self-digestion. Nature, 451, 1069-1075.
28. Moreau, P., Richardson, P.G., Cavo, M., Orlowski, R.Z., San Miguel, J.F., Palumbo, A. & Harousseau, J.L. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120, 947-959.
29. Muqit, M.M., Davidson, S.M., Payne Smith, M.D., MacCormac, L.P., Kahns, S., Jensen, P.H., Wood, N.W. & Latchman, D.S. (2004) Parkin is recruited into aggresomes in a stress-specific manner: over-expression of Parkin reduces aggresome formation but can be dissociated from Parkin's effect on neuronal survival. Human Molecular Genetics, 13, 117-135.
30. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J. Jr, Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907-4916.
31. Ohsumi, Y. (2001) Molecular dissection of autophagy: two ubiquitin-like systems. Nature Reviews Molecular Cell Biology, 2, 211-216.
32. Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Øvervatn, A., Bjørkøy, G. & Johansen, T. (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. Journal of Biological Chemistry, 282, 24131-24145.
33. Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 114, 3439-3447.
34. Raje, N., Hideshima, T., Mukherjee, S., Raab, M., Vallet, S., Chhetri, S., Cirstea, D., Pozzi, S., Mitsiades, C., Rooney, M., Kiziltepe, T., Podar, K., Okawa, Y., Ikeda, H., Carrasco, R., Richardson, P.G., Chauhan, D., Munshi, N.C., Sharma, S., Parikh, H., Chabner, B., Scadden, D. & Anderson, K.C. (2009) Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia, 23, 961-970.
35. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D.H., Rajkumar, S.V., Srkalovic, G., Alsina, M. & Anderson, K.C. (2006) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer, 106, 1316-1319.
36. Richardson, P.G., Hungria, V.T.M., Yoon, S.-S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Guenther, A., Nakorn, T.N., Siritanaratkul, N., Schlossman, R.L., Hou, J., Moreau, P., Lonial, S., Lee, J.H., Einsele, H., Sopala, M., Bengoudifa, B.-R., Corrado, C. & San-Miguel, J.F. (2014) Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. ASCO Annual Meeting, 32, 5s (Suppl.; abstr 8510).
37. Rodriguez-Gonzalez, A., Lin, T., Ikeda, A.K., Simms-Waldrip, T., Fu, C. & Sakamoto, K.M. (2008) Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Research, 68, 2557-2560.
38. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H., Richardson, P.G. & VISTA Trial Investigators. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
39. Santo, L., Vallet, S., Hideshima, T., Cirstea, D., Ikeda, H., Pozzi, S., Patel, K., Okawa, Y., Gorgun, G., Perrone, G., Calabrese, E., Yule, M., Squires, M., Ladetto, M., Boccadoro, M., Richardson, P.G., Munshi, N.C., Anderson, K.C. & Raje, N. (2010) AT7519, a novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene, 29, 2325-2336.
40. Santo, L., Hideshima, T., Kung, A.L., Tseng, J.C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J.H., Mazitschek, R., Ogier, W.C., Cirstea, D., Rodig, S., Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K.C., Jones, S.S. & Raje, N. (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 119, 2579-2589.
41. Schewe, D.M. & Aguirre-Ghiso, J.A. (2009) Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Research, 69, 1545-1552.
42. Siegel, D.S., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., Chanan-Khan, A., Buadi, F., Reu, F.J., Somlo, G., Zonder, J., Song, K., Stewart, A.K., Stadtmauer, E., Kunkel, L., Wear, S., Wong, A.F., Orlowski, R.Z. & Jagannath, S. (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 120, 2817-2825.
43. Simms-Waldrip, T., Rodriguez-Gonzalez, A., Lin, T., Ikeda, A.K., Fu, C. & Sakamoto, K.M. (2008) The aggresome pathway as a target for therapy in hematologic malignancies. Molecular Genetics and Metabolism, 94, 283-286.
44. Ugbode, C.I., Hirst, W.D. & Rattray, M. (2014) Neuronal influences are necessary to produce mitochondrial co-localization with glutamate transporters in astrocytes. Journal of Neurochemistry, 130, 668-677.
45. White-Gilbertson, S., Hua, Y. & Liu, B. (2013) The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Frontiers in Genetics, 4, 109.
46. Yao, T.P. (2010) The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes & Cancer, 1, 779-786.
47. Zang, Y., Thomas, S.M., Chan, E.T., Kirk, C.J., Freilino, M.L., DeLancey, H.M., Grandis, J.R., Li, C. & Johnson, D.E. (2012) Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research, 18, 5639-5649.